Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improv
Germany’s Merck KGaA said this morning that the FDA has placed a partial clinical hold on its multiple sclerosis drug candidate evobrutinib, vying to become a new oral the
Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta (
Biogen's efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China's InnoCare last year f
Ben Hargreaves examines why a research project in the UK could provide key insights to develop treatments against many of the most prominent diseases impacting society.
While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer, and AstraZeneca is hoping to change
